Trump taking momentum out of healthcare stocks, says analyst

24 February 2017

The mixed messages on drug pricing policy coming from new US President Donald Trump’s administration are starting to harm healthcare stocks, according to an analyst at the independent broker finnCap.

Mark Brewer states in his Life Sciences quarterly sector note – Rude Health – that he believes that investors could now turn their attention to the diagnostics sector.

“Pharmaceutical pricing pressure remains post the US election with a focus on headline costs per patient,” the note states, citing companies which have come under fire for their prices and been forced into a response, including Netherlands-incorporated Mylan (Nasdaq: MYL) and privately-held Marathon Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK